Akèy › Dematit atopik (Ekzema) › Michigan
Etid klinik pou Dematit atopik (Ekzema) nan Michigan
14 etid pou Dematit atopik (Ekzema) ap chèche patisipan nan sit nan Michigan.
Vil nan Michigan
Tèks ofisyèl etid la (Anglè)
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- David Fivenson, MD, Dermatology, PLLC- Site Number : 8400017, Ann Arbor
- Oakland Hills Dermatology- Site Number : 8400042, Auburn Hills
- Great Lakes Research Group - Bay City- Site Number : 8400052, Bay City
- ak 3 plis
Ap rekriteEtid obsèvasyon
Laj 12 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07290803Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Troy
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Auburn Hills
- Enveda Investigative Site, Bay City
- Enveda Investigative Site, Clinton Township
- ak 1 plis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT07298395A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Detroit
- Investigational Site, Troy
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07003425Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
- Derm Research Institute, PLC, Caledonia
Ap rekriteEtid obsèvasyon
Laj 12 a 89 · Tout sèks · Mizajou Sep 15, 2026 · NCT07645820A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
- Revival Research Institute, LLC, Troy
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07223697FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- Revival Research Institute, LLC, Troy
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 70 · Tout sèks · Mizajou Jul 22, 2026 · NCT06564389A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, Waterford
Ap rekriteFaz 3
6 Months – 11 Years · Tout sèks · Mizajou Jul 7, 2026 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Henry Ford Medical Center - New Center One /ID# 263522, Detroit
Ap rekriteFaz 3
Laj 18 a 63 · Tout sèks · Mizajou Jul 6, 2026 · NCT06389136A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Michigan Center for Research Company, Clarkston
- MI Skin Innovations, Northville
- Revival Research Institute LLC, Troy
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 4, 2026 · NCT05995964Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 7066, Auburn Hills
- Galderma Investigational Site 7071, Caledonia
- Galderma Investigational Site 7108, Grandville
- ak 1 plis
Ap rekriteEtid obsèvasyon
Laj 12 ak plis · Tout sèks · Mizajou Mar 13, 2026 · NCT06988605Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
- University of Michigan, Ann Arbor
Ap rekriteVolontè an sante akeyi
Laj 10 a 55 · Tout sèks · Mizajou Nov 25, 2025 · NCT06300697Ethnic Differences in Mechanisms of Action of Dupilumab
- University of Michigan, Ann Arbor
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Nov 6, 2025 · NCT05268107A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
- University of Michigan Health System - Ann Arbor /ID# 267275, Ann Arbor
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Jan 24, 2025 · NCT06524635Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.